Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Deleted in esophageal cancer 1 is an RNA gene located on chromosome 9q33.1, commonly deleted in esophageal squamous cell carcinomas, with reduced or absent expression in these tumors. It is considered a candidate tumor suppressor gene due to its frequent loss or reduction in expression in multiple cancers. DELEC1 is categorized as a long non-coding RNA (lncRNA) gene and is not confirmed to encode a protein. Current research has not delineated a specific biological function or molecular mechanism, and no established drugs, clinical biomarkers, or safety concerns are documented in relation to this gene. Some literature and database entries inadvertently conflate DELEC1 with DLEC1, which is a protein-coding tumor suppressor involved in cell proliferation and may have different functionalities. If your context is strictly about the DELEC1 gene on chromosome 9 annotated as a non-coding RNA, it is best considered a putative tumor suppressor and not a validated drug target or receptor.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Deleted in esophageal cancer 1 (DELEC1).